Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $74.5 million.

  • Mimedx's Total Non-Current Liabilities rose 2428.66% to $74.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.5 million, marking a year-over-year increase of 2428.66%. This contributed to the annual value of $63.4 million for FY2024, which is 3260.33% down from last year.
  • Mimedx's Total Non-Current Liabilities amounted to $74.5 million in Q3 2025, which was up 2428.66% from $67.5 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Total Non-Current Liabilities ranged from a high of $103.2 million in Q1 2021 and a low of $58.3 million during Q2 2024
  • For the 5-year period, Mimedx's Total Non-Current Liabilities averaged around $81.7 million, with its median value being $89.6 million (2023).
  • In the last 5 years, Mimedx's Total Non-Current Liabilities tumbled by 3755.39% in 2024 and then skyrocketed by 2428.66% in 2025.
  • Mimedx's Total Non-Current Liabilities (Quarter) stood at $90.5 million in 2021, then grew by 1.84% to $92.2 million in 2022, then increased by 2.12% to $94.1 million in 2023, then plummeted by 32.6% to $63.4 million in 2024, then rose by 17.49% to $74.5 million in 2025.
  • Its Total Non-Current Liabilities stands at $74.5 million for Q3 2025, versus $67.5 million for Q2 2025 and $60.2 million for Q1 2025.